You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Previously Failed, Platinum-Containing Chemotherapy Regimens

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced or Metastatic NSCLC Trial (Utidelone Injection, Docetaxel Injection)

Not yet recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Utidelone Injection
  • Docetaxel Injection
  • (no location specified)
Dec 30, 2022

Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and

Recruiting
  • Untreated Advanced Non-small Cell Lung Cancer
  • Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Nov 13, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Urothelial Cancer Trial in Beijing (Atezolizumab, RO7247669, Tiragolumab)

Recruiting
  • Urothelial Cancer
  • Beijing, China
    Beijing Cancer Hospital
Jan 18, 2023

Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)

Active, not recruiting
  • Metastatic Urothelial Cancer
  • Enfortumab vedotin
  • Beijing, China
  • +7 more
Aug 23, 2022

Small Cell Lung Cancer Trial in Beijing (Gimatecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of General Hospital of the Chinese Peop
Aug 2, 2020

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Malignant Pleural Mesothelioma Trial in Worldwide (rAd-IFN, Celecoxib Oral Product, Gemcitabine)

Active, not recruiting
  • Malignant Pleural Mesothelioma
  • rAd-IFN
  • +2 more
  • Los Angeles, California
  • +41 more
Oct 25, 2021

NSCLC Trial in Changsha (envafolimab)

Enrolling by invitation
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    the second Xiangya hospital
May 1, 2022

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Biliary Tract Cancer Trial in Seoul (Pemetrexed 500 MG, Erlotinib)

Recruiting
  • Biliary Tract Cancer
  • Seoul, Korea, Republic of
  • +1 more
Jun 13, 2022

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

NSCLC Trial in Changsha (Sintilimab Combined With Docetaxel)

Completed
  • Non-small Cell Lung Cancer
  • Sintilimab Combined With Docetaxel
  • Changsha, Hunan, China
    Hunan Provincal Tumor Hospital
Mar 1, 2022

Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)

Not yet recruiting
  • Cervical Cancer
  • Bengbu, Anhui, China
  • +11 more
Nov 23, 2023

Effectiveness, Sexuality Trial in Zhengzhou (Lenvatinib mesylate capsule)

Not yet recruiting
  • Effectiveness
  • Sexuality
  • Lenvatinib mesylate capsule
  • Zhengzhou, Henan, China
    Department of Bone and Soft Tissue ,Henan Cancer Hospital
Jan 31, 2023

Locally Advanced or Metastatic NSCLC Trial (HB1801, Taxotere)

Not yet recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Advanced Solid Tumor Trial in China (Anti-PD-1 mAb)

Active, not recruiting
  • Advanced Solid Tumor
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
  • +29 more
Mar 2, 2021

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer Trial in Nanjing (Sintilimab + Anlotinib +

Recruiting
  • Metastatic NSCLC
  • +2 more
  • Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin
  • Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Aug 10, 2021

Non Small Cell Lung Cancer Trial in China (Efgbemalenograstim alfa)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Efgbemalenograstim alfa
  • Zhengzhou, Henan, China
  • +9 more
Nov 16, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in Shanghai (MRG003, Cetuximab injection, Methotrexate Injection)

Not yet recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Feb 21, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Worldwide (Nivolumab, Docetaxel)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Beijing, Beijing, China
  • +31 more
Jul 21, 2022

Cancer of Unknown Primary Site Trial in Worldwide (Alectinib, Vismodegib, Ipatasertib)

Active, not recruiting
  • Cancer of Unknown Primary Site
  • Blacktown, New South Wales, Australia
  • +140 more
Jan 6, 2023

Triple-negative Breast Cancer Trial in United States (Paclitaxel, Carboplatin, Doxorubicin)

Completed
Has Results
  • Triple-negative Breast Cancer
  • Fairway, Kansas
  • +8 more
May 6, 2021